Medical Advocates
Pegylated Interferon alfa-2a (Pegasys)
 
HCV Indications

New and Noteworthy      HIV/HCV Coinfection
 General Reports             Children
 Pharmacokinetics
 Viral Dynamics
 Efficacy
 Adverse Events
 Transplants
 Treatment Strategies
Discontinuation of Therapy
Special Populations
 Quality of Life
 Pharmacoeconomics

  
Peg Inf alfa 2a Main Main New/Newsworthy Home Page
Last Update:  January 03, 2009
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
January 2009
 
December 2008
 
General Reports
 

      Journal Papers, Abstracts, and Commentaries

 
A WEEK IN REVIEW FEATURED REPORT
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with
peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
 Rodríguez-Torres M, Ríos-Bedoya CF, et al
J Med Virol. 2008 Jul 22;80(9):1576-1580.
 Abstract
 
The impact of combination therapy with peginterferon alfa-2a and ribavirin on the energy intake a
nd body weight of adult hepatitis C patients.
Hamer C.  
J Hum Nutr Diet. 2008 Jul 18
 Abstract
 
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection
treated with peginterferon alfa-2a plus ribavirin.
 Bain VG, Lee SS, Peltekian K,  et al   
Aliment Pharmacol Ther. 2008 Apr 7
 Abstract
 
Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3*4A protease
inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a.
 Gelderblom HC, Zeuzem S, Weegink CJ, et al 
Scand J Gastroenterol. 2008 Apr 10:1-6.
 Abstract
 
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin
in chronic hepatitis C between genotypes 2 and 3.
Powis J, Peltekian KM, Lee SS, et al
 J Viral Hepat. 2008 Jan;15(1):52-7.
 Abstract
 
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying
molecular pathways for treatment response.
 Feld JJ, Nanda S, Huang Y, et al
Hepatology. 2007 Oct 10;
Abstract
 
Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a.
Thomas T, Foster G.
Int J Nanomedicine. 2007;2(1):19-24.
 Abstract
 
FULL-TEXT DOCUMENT
Adult systemic cat scratch disease associated with therapy for hepatitis C.
Bhatti Z, Berenson CS.
BMC Infect Dis. 2007 Feb 23;7:8.
Paper
 
Peginterferon alfa-2a: A review of approved and investigational uses.
Matthews SJ, McCoy C.
 Clin Ther. 2004 Jul;26(7):991-1025.
Abstract
Pharmacokinetics
 

      Journal Papers, Abstracts, and Commentaries

  Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: A meta-analysis of
individual patient data.
 Camma C, Di Bona D, Schepis F, et al 
Hepatology. 2004 Feb;39(2):333-42.
Abstract
Viral Dynamics
 

      Journal Papers, Abstracts, and Commentaries

 
Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b
plus ribavirin treatment in patients with chronic hepatitis C.
Di Bisceglie AM, Ghalib RH, Hamzeh FM, Rustgi VK.
J Viral Hepat. 2007 Oct;14(10):72
 Abstract
 
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype
3/HIV co-infected patients.
 Crespo M, Esteban JI, Ribera E, et al
AIDS. 2007 Feb 19;21(4):477-481.
Abstract
 
Prediction of sustained virological response in chronic hepatitis C patients treated with
peginterferon alfa-2a (40KD) and ribavirin.
 Foster GR, Fried MW, Hadziyannis SJ  
Scand J Gastroenterol. 2007 Feb;42(2):247-55.
 Abstract

Pegylated interferon alpha therapy in acute hepatitis C: Relation to hepatitis C virus-specific
T cell response kinetics.
 Kamal SM, Ismail A, Graham , et al
Hepatology. 2004 Jun;39(6):1721-31.
 tract
 
  Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a
(40KD).
 Lee S, Heathcote E, Reddy K,  et al
 J Hepatol 2002 Oct;37(4):500
Abstract
Efficacy
Transplants
Peg Interferon alfa-2a

      Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT PDF ARTICLE
 Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and
delayed treatment with 12 weeks of pegylated interferon alfa-2a.
 Sharaf Eldin N, Ismail S, et al  
PLoS ONE. 2008;3(12):e4085.
 Paper
 
Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2
and low viral load: A pilot, randomized study.
 Tsubota A, Satoh K, Aizawa M, et al
World J Gastroenterol. 2008 Dec 21;14(47):7220-4
 Abstract
 
Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial
treatment of chronic hepatitis C virus: Prospective, non-randomized study.
 Escudero A, Rodríguez F, Serra MA, et al 
J Gastroenterol Hepatol. 2008 Apr 19
 Abstract
 
Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype
1-infected slow responders.
 Pearlman BL, Ehleben C, Saifee S.
Hepatology. 2007 Nov 28;46(6):1688-1694
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus
infection: a cost-utility analysis from the perspective of the Veterans Affairs Health Care
system.
 Yeh WS, Armstrong EP, Skrepnek GH, Malone DC.
Pharmacotherapy. 2007 Jun;27(6):813-24.
Abstract
 
A short course of pegylated interferon-alpha in acute HCV hepatitis.
 Calleri G, Cariti G, Gaiottino F, et al  
J Viral Hepat. 2007 Feb;14(2):116-121.
 Abstract

Peginterferon-alpha(2a) (40 kDa) for chronic hepatitis C.
 Hadziyannis SJ, Papatheodoridis GV.
Expert Opin Pharmacother 2003 Apr;4(4):541-551
 Abstract

Peginterferon alfa-2a (40KD) (Pegasys) for the treatment of patients with chronic hepatitis C.
 Ferenci P.
 Int J Clin Pract. 2003 Sep;57(7):610-5.
 Abstract
 
       Conference Reports, Abstracts, and Posters 
 
  Evaluation of Two Doses of Peginterferon Alfa-2a for the Treatment of Chronic Hepatitis C (CHC)
PJ POCKROS, R CARITHERS, P DESMOND, et al
 (41 ICAAC)
Abstract

Peg Interferon alfa-2a/Ribavirin

      Journal Papers, Abstracts, and Commentaries
 
 
Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected
patients with genotype 1: Results of a retrospective evaluation.
Zopf S, Herold C, Hahn EG, Ganslmayer M.  
Scand J Gastroenterol. 2008 Dec 31:1-5.
 Abstract
 
Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with
chronic hepatitis C.
 Njouom R, Sartre MT, Timba I,  et al  
J Med Virol. 2008 Dec;80(12):2079-85.
 Abstract
 
A WEEK IN REVIEW FEATURED REPORT
 Swiss Multicenter Study Evaluating the Efficacy, Feasibility and Safety of Peginterferon-Alfa-2a and Ribavirin
in Patients with Chronic Hepatitis C in Official Opiate Substitution Programs.
 Fried R, Monnat M, Seidenberg A, et al 
Digestion. 2008 Nov 21;78(2-3):123-130
 Abstract
 
Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological
responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and
amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with
chronic hepatitis C.
 Angelico M, Koehler-Horst B, Piccolo P, et al  
Eur J Gastroenterol Hepatol. 2008 Jul;20(7):680-7.
 Abstract
 
Peginterferon-alpha-2a (40 kD) Plus Ribavirin: A Review of its Use in the Management of Chronic
Hepatitis C Mono-Infection.
 Keam SJ, Cvetković RS. 
Drugs. 2008;68(9):1273-317.
 Abstract
 
Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With
Rapid Virological Response.
 Ferenci P, Laferl H, Scherzer TM, et al  Gastroenterology. 2008 May 23.
 Abstract
 
Chronic hepatitis C treatment with pegylated interferon alpha2a and ribavirin in patients
with HIV-infection.
 [No authors listed] 
Ter Arkh. 2007;79(11):40-4.
 Abstract
 
Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C
in clinical practice: The German Open Safety Trial.
 Witthöft T, Möller B, Wiedmann KH, et al 
J Viral Hepat. 2007 Nov;14(11):788-96.
 Abstract
 
Global transcriptional effects of PEG-IFN-alpha and ribavirin on peripheral blood cells obtained
from patients with chronic hepatitis C.
 Balan V, Aravind L, Grill DE, Therneau TM, et al 
Hepatol Res. 2006 Oct 6;
Abstract
 
Interferon (IFN)- gamma -Inducible Protein-10: Association with Histological Results,
Viral Kinetics, and Outcome during Treatment with Pegylated IFN- alpha 2a and Ribavirin
for Chronic Hepatitis C Virus Infection.
 Romero AI, Lagging M, Westin J, et al 
J Infect Dis. 2006 Oct 1;194(7):895-903.
 Abstract
 
Short-term therapy with pegylated interferon plus ribavirin for the chronic hepatitis C genotype
2 patients
Jung EU, Park JH, Pae KI
Korean J Hepatol. 2007 Sep;13(3):341-8.
 Abstract
 
CD4+ T Cell Responses in Patients with Chronic Hepatitis C Undergoing Peginterferon/Ribavirin
Therapy Correlate with Faster, but Not Sustained, Viral Clearance.
 Aberle JH, Perstinger G, Weseslindtner L, et al
J Infect Dis. 2007 May 1;195(9):1315-9.
 Abstract
 
Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated
interferon-alpha and ribavirin.
 Trebst C, Wedemeyer H, Manns MP, et al 
Eur J Gastroenterol Hepatol. 2007 Jan;19(1):91-2.
 Abstract
 
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous
interferon therapy.
 Sherman M, Yoshida EM, Deschenes Mm et al 
Gut. 2006 May 18;
Abstract

A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a
plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients
with chronic hepatitis C.
Mangia A, Ricci GL, Persico M, et al
J Viral Hepat. 2005 May;12(3):292-299
 Abstract
 
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection in HIV-Infected
Patients.
 Torriani FJ, Rodriguez-Torres M, Rockstroh, et al 
N Engl J Med. 2004 Jul 29;351(5):438-450.
 Abstract
 
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and
normal aminotransferase levels.
Zeuze S, Diago M, Gane E, et al  
Gastroenterology. 2004 Dec;127(6):1724-32
 Abstract|
 
Peg Interferon alfa-2a vs Standard Interferon alfa-2a

       Journal Papers, Abstracts, and Commentaries
 
 
Peginterferon vs. standard interferon in the treatment of chronic hepatitis C.
 Zaman A, Fennerty MB, Keeffe EB.
Aliment Pharmacol Ther. 2003 Oct;18(7):661-70.
Abstract

Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon
alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
 Pockros PJ, Carithers R, Desmond P, et al  
Am J Gastroenterol. 2004 Jul;99(7):1298-305.
 Abstract
Transplants
 

      Journal Papers, Abstracts, and Commentaries

 
The treatment of chronic hepatitis C with peginterferon alfa-2a (40kDa) plus ribavirin in
haemodialysed patients awaiting renal transplant.
 Rendina M, Schena A, Castellaneta NM, et al
J Hepatol. 2007 Feb 5;
Abstract
 
Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver
transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S, Lyden E.
Hepatogastroenterology. 2006 Jul-Aug;53(70):561-5
 Abstract

Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials.
 Chalasani N, Manzarbeitia C, Ferenci P,et al  
Hepatology. 2005 Jan 19;41(2):289-298
Abstract

Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
 Mukherjee S.
 Transplant Proc. 2005 Dec;37(10):4403-5.
Abstract
Adverse Events
 

      Journal Papers, Abstracts, and Commentaries

 
Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in
chronic hepatitis C patients.
 Pawelczyk T, Pawelczyk A, Strzelecki D, Rabe-Jablonska J.
Gen Hosp Psychiatry. 2008 Nov-Dec;30(6):501-8.
 Abstract
 
Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during
pegylated interferon alpha and ribavirin therapy.
 Hofmann WP, Kronenberger B, Bojunga J, et al  
J Viral Hepat. 2008 Jul 28.
 Abstract
 
Incidence of Neutropenia and Infections During Combination Treatment of Chronic Hepatitis C with Pegylated Interferon
Alfa-2a or Alfa-2b Plus Ribavirin.
 Antonini MG, Babudieri S, Maida I, et al 
Infection. 2008 May 3
 Abstract
 
Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and
ribavirin.
 Vartany E, Caldwell CA, Trow TK. 
Heart Lung. 2008 Mar-Apr;37(2):153-6.
 Abstract
 
Bacterial endocarditis in the course of sepsis in 7th month of treatment with peginterferon alfa
and ribavirin in patient with chronic hepatitis C
 Bolewska B, Juszczyk J, Wojtacha A.
Wiad Lek. 2007;60(9-10):462-5.
 Abstract
 
Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a
therapy for chronic hepatitis C virus infection.
 Khiani V, Kelly T, Shibli A, et a
 World J Gastroenterol. 2008 Jan 14;14(2):318-21.
 Abstract
 
Severe stomatitis complicating treatment with pegylated-interferon alpha-2a and ribavirin in an
HCV-infected patient.
 Borrás-Blasco J, Primo J, Rosique-Robles JD, et al  
South Med J. 2008 Jan;101(1):88-90.
 Abstract
 
Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a
therapy for chronic hepatitis C virus infection.
 Khiani V, Kelly T, Shibli A, et al
World J Gastroenterol. 2008 Jan 14;14(2):318-21
Abstract
 
Severe stomatitis complicating treatment with pegylated-interferon alpha-2a and ribavirin in an
HCV-infected patient.
 Borrás-Blasco J, Primo J, Rosique-Robles JD, et al  
South Med J. 2008 Jan;101(1):88-90.
 Abstract
 
De novo depression and anxiety disorders and influence on adherence during
peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C.
 Martín-Santos R, Díez-Quevedo C, Castellví P, et al 
Aliment Pharmacol Ther. 2007 Nov 6
Abstract
 
Toxicity of the treatment of chronic hepatitis C with peginterferon a (2a or 2b) plus ribavirin
in patients not previously treated
Márquez Peiró JF, Valero Alcocer VE, Morales Suárez-Varela M, et al
Med Clin (Barc). 2007 Nov 3;129(16):612-4.
Abstract
 
UK prospective study of change in visual function in patients treated with Peginterferon alpha
for hepatitis C.
 Malik NN, Sheth HG, Ackerman N, et al
Br J Ophthalmol. 2007 Oct 25;
Abstract
 
FULL-TEXT ARTICLE
 Sudden hearing loss associated with peginterferon and ribavirin combination therapy during
hepatitis C treatment.
 Elloumi H, Houissa F, Hadj NB, et al 
World J Gastroenterol. 2007 Oct 28;13(40):5411-2.
 Paper
 
Pulmonary Toxicity by Pegylated Interferon alpha-2a in a Patient with Chronic Hepatitis C.
 Son BK, Sohn JH, Kim TY, Park YK, Jeon YC, Han DS.
 Korean J Hepatol. 2007 Mar;13(1):103-7
 Abstract
 
Neck pain and fever after peginterferon alpha-2a
 Moser C, Furrer J, Ruggieri F.  
Schweiz Rundsch Med Prax. 2007 Feb 7;96(6):205-7
 Abstract
 
Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic
hepatitis C.
 Leung Y, Urbanski SJ, Schindel L, Myers RP. 
Can J Gastroenterol. 2006 Oct;20(10):661-3.
 Abstract

Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment
with peginterferon alfa-2a and ribavirin.
 Cauli C, Serra G, Chessa L, et al;
Haematologica. 2006 Jun;91(6 Suppl):
 Abstract
 
Sudden hearing loss in patients with chronic hepatitis C treated with pegylated
interferon/ribavirin.
 Formann E, Stauber R, Denk DM, et al.
 Am J Gastroenterol. 2004 May;99(5):873-7
 Abstract

Treatment Strategies
 
     Journal Papers, Abstracts, and Commentaries
 
 
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
 Di Bisceglie AM, Shiffman ML, Everson GT ,et al
N Engl J Med. 2008 Dec 4;359(23):2429-41.
 Abstract
 
Optimizing dosage and duration therapy for chronic hepatitis C difficult-to-treat patients.
 Ladero JM.
Ann Hepatol. 2008 Oct-Dec;7(4):392-4.
 Abstract
 
Swiss Multicenter Study Evaluating the Efficacy, Feasibility and Safety of Peginterferon-Alfa-2a and Ribavirin
in Patients with Chronic Hepatitis C in Official Opiate Substitution Programs.
 Fried R, Monnat M, Seidenberg A, et al 
Digestion. 2008 Nov 21;78(2-3):123-130
 Abstract
 
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks
in chronic hepatitis C virus-1 infection.
von Wagner M, Hofmann WP, Teuber G, et al
Hepatology. 2008 Jun 19.
Abstract
 
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study
of higher doses of peginterferon alpha-2a and ribavirin.
Fried MW, Jensen DM, Rodriguez-Torres M, et al
Hepatology. 2008 Jun 9.
Abstract
 
Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus
ribavirin.
Tang KH, Herrmann E, Pachiadakis I, et al
Aliment Pharmacol Ther. 2008 May;27(9):810-9
 Abstract

Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in hcv-related
decompensated cirrhotics.
 Tekin F, Gunsar F, Karasu Z, et al  
Aliment Pharmacol Ther. 2008 Mar 14
Abstract